Marshall Wace, LLP Homology Medicines, Inc. Transaction History

Marshall Wace, LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$1.09 - $2.04 $10,246 - $19,176	-9,400 Reduced 31.15%	20,775 $26,000
Q3 2022 Nov 14, 2022	BUY	$1.55 - $3.01 $13,467 - $26,153	8,689 Added 40.44%	30,175 $48,000
Q2 2022 Aug 15, 2022	SELL	$1.39 - $3.12 $535,031 - $1.2 Million	-384,915 Reduced 94.71%	21,486 $42,000
Q2 2021 Aug 13, 2021	BUY	$6.02 - $9.64 $2.45 Million - $3.92 Million	406,401 New	406,401 $2.95 Million
Q2 2020 Aug 13, 2020	SELL	$12.07 - $19.34 $52,601 - $84,283	-4,358 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$12.5 - $22.04 $54,475 - $96,050	4,358 New	4,358 $68,000
Q4 2019 Feb 14, 2020	SELL	$11.42 - $22.19 $23,433 - $45,533	-2,052 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$14.74 - $22.28 $194,405 - $293,850	-13,189 Reduced 86.54%	2,052 $37,000
Q2 2019 Aug 14, 2019	BUY	$18.35 - $30.34 $230,677 - $381,404	12,571 Added 470.82%	15,241 $298,000
Q1 2019 May 14, 2019	BUY	$19.76 - $29.57 $52,759 - $78,951	2,670 New	2,670 $74,000

66.2K

Ticker FIXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 57,402,000
Description
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.